metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib plus capecitabine
	neratinib plus capecitabine vs. lapatinib plus capecitabine	2	statistically conclusive 26 % decrease in progression or deaths (PFS) suggested 50 % decrease in DOR	inconclusive results for: deaths (OS); objective responses (ORR); Anaemia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Constipation AE (grade 3-4); Decreased appetite AE (grade 3-4); Diarrhoea AE (grade 3-4); Fatigue AE (grade 3-4); Headache AE (grade 3-4); Nausea AE (grade 3-4); Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4); Pyrexia AE (grade 3-4); Rash AE (grade 3-4); Stomatitis AE (grade 3-4); Vomiting AE (grade 3-4); Weight decreased AE (grade 3-4)	-	-
versus placebo
	neratinib vs. placebo	1	none	-	-	-
versus trastuzumab plus capecitabine
	tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine	2	none	inconclusive results for: AE leading to treatment discontinuation (any grade)	statistically conclusive 34 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 46 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-